A Phase 1 Single Ascending Dose study of JN-0413
Latest Information Update: 21 Aug 2026
At a glance
- Drugs JN 0413 (Primary)
- Indications Cognition disorders
- Focus Adverse reactions; First in man
- Sponsors Jocasta Neuroscience
Most Recent Events
- 19 Aug 2026 According to a Jocasta Neuroscience media release, company expects to begin the trial at the start of 2027.
- 14 Oct 2025 New trial record